Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 8557857

Angiogenesis.

R A Swerlick
View original source ↗Export metadata ↓

Abstract

The formation of new blood vessels, angiogenesis, is a complex process which is central to normal development and homeostasis. However, uncontrolled angiogenesis plays a critical role in both inflammatory and neoplastic disorders. Our understanding of angiogenesis has expanded greatly over the past two decades due to the development of in vivo and in vitro models to study this important process. A variety of cytokines and growth factors have been shown to induce new blood vessel formation in vivo, and in vitro studies have been able to define whether agents have direct or indirect effects upon vascular endothelial cells. Our improved understanding of the mechanisms which regulate angiogenesis has now created important opportunities for the development of new therapies for the treatment of inflammatory and neoplastic skin disease.

Explore related subjects

Endothelial Growth FactorsFibroblast Growth FactorsHumansLymphokinesNeovascularization, PathologicNeovascularization, PhysiologicTransforming Growth Factor betaVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R A Swerlick. 1995. Angiogenesis.. https://doi.org/10.1111/j.1346-8138.1995.tb03934.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2000

Receptor-selective variants of human vascular endothelial growth factor. Generation and characterization.

Vascular endothelial growth factor (VEGF) is a pleiotropic factor that exerts a multitude of biological effects through its interaction with two receptor tyrosine kinases, fms-like tyrosine kinase (Flt-1) or VEGF receptor 1 and kinase insert domain-containing receptor (KDR) or VEGF receptor 2. Whereas it is commonly accepted that KDR is responsible for the proliferative activities of VEGF, considerable controversy and uncertainty exist about the role of the individual receptors in eliciting many of the other effects. Based on a comprehensive mutational analysis of the receptor-binding site of VEGF, an Flt-1-selective variant was created containing four substitutions from the wild-type protein. This variant bound with wild-type affinity to Flt-1, was at least 470-fold reduced in binding to KDR, and had no activity in cell-based assays measuring autophosphorylation of KDR or proliferation of primary human vascular endothelial cells. Using a competitive phage display strategy, two KDR-selective variants were discovered with three and four changes from wild-type, respectively. Both variants had approximately wild-type affinity for KDR, were about 2000-fold reduced in binding to Flt-1, and showed activity comparable with the wild-type protein in KDR autophosphorylation and endothelial cell proliferation assays. These variants will serve as useful reagents in elucidating the roles of Flt-1 and KDR.

Endothelial Growth Factors↗
PubMed2000

VEGF overexpression in clinically localized prostate tumors and neuropilin-1 overexpression in metastatic forms.

Studies comparing tumor neovascularity with pathological findings suggest that angiogenesis contributes to the pathogenesis of prostate cancer. We have examined 42 primary sporadic prostate tumors at different clinical stages, together with 3 prostate cancer cell lines (DU145, PC3 and LNCaP), for expression of VEGF and the gene encoding the recently identified VEGF165 isoform-specific receptor neuropilin-1, by using a quantitative reverse transcription (RT)-PCR method. We also evaluated the VEGF transcription pattern. Upregulation of VEGF and neuropilin-1 was observed in 12 and 14 tumors, respectively. The VEGF165 isoform was slighly overrepresented in tumors that overexpressed VEGF. VEGF overexpression correlated with stage II disease (p < 0.05); neuropilin-1 overexpression correlated with advanced disease (p < 0. 01) and a high Gleason grade (p < 0.02). Our observations suggest that VEGF expression could be used as a prognostic marker in early-stage prostate tumors, whereas neuropilin-1 overexpression might be a marker of aggressiveness.

Endothelial Growth Factors↗